Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Bullish +75

EW's Q1 Earnings Beat, Revenues Match, '26 View Up, Stock Climbs

AI-generated analysis

Edwards Lifesciences reported first-quarter 2026 adjusted EPS of $0.78, beating analyst estimates by 16.4% and rising 21.9% year-over-year.

Total Q1 revenue was $1.65 billion, matching the Zacks Consensus Estimate and increasing 17% compared to the prior year.

Stock price climbed 2.3% in aftermarket trading following the earnings announcement of strong financial performance.

TAVR segment sales reached $1.20 billion, reflecting increased clinician adoption of SAPIEN therapy and proactive management of severe aortic stenosis patients.

TMTT unit revenue grew 51.9% year-over-year to $175.1 million, driven by global adoption of PASCAL and EVOQUE product lines.

Surgical sales rose 10.1% year-over-year, primarily due to continued expansion of RESILIA therapies that offer extended durability.

Gross profit increased 15.7% to $1.29 billion, though the gross margin contracted by 64 basis points to 78% due to higher cost of sales.

Operating income expanded significantly by 28.1% year-over-year to $500.5 million, resulting in an operating margin expansion of 269 basis points.

The company ended Q1 with $2.40 billion in cash and cash equivalents, while total debt remained stable at roughly $600 million.

Management raised its full-year 2026 sales growth guidance to between 9% and 11%, citing strong catalysts and differentiated therapies.

For the second quarter of 2026, Edwards projects sales between $1.66 billion and $1.74 billion with adjusted EPS between 70 and 76 cents.

Analysts noted that while gross margin contraction is a concern, the expansion in operating margins signals positive operational efficiency.

Zacks Investment Research assigns Edwards Lifesciences a Rank #3 (Hold) based on its current market valuation and earnings trajectory.

The broader medical device sector saw other notable performers like Globus Medical with a Rank #1 (Strong Buy) rating following their own Q4 beat.

Globus Medical reported fourth-quarter 2025 adjusted EPS of $1.28 and revenue of $826.4 million, both surpassing analyst expectations.

Tactile Systems Technology achieved a Rank #2 (Buy) status with Q4 EPS of $0.46 and revenues of $103.6 million beating estimates.

Phibro Animal Health displayed strong consistency with positive earnings surprise in each of its last four quarters of fiscal 2026.

These recommendations suggest diversification opportunities for investors looking beyond Edwards Lifesciences within the healthcare technology space.

Bullish Signals
  • Edwards Lifesciences beat Q1 earnings estimates with adjusted EPS of 78 cents, exceeding the consensus by 16.4% and marking a 21.9% year-over-year increase.
  • Sales reached $1.65 billion, aligning perfectly with analyst expectations while growing 17% year over year to demonstrate strong demand.
  • The TAVR segment drove significant growth with global sales up 14.4% to $1.20 billion, fueled by increased adoption of the SAPIEN 3 Ultra RESILIA platform.
  • Transcatheter Mitral and Tricuspid Therapies saw explosive growth, with sales surging 51.9% year over year as clinicians adopt PASCAL and EVOQUE devices.
  • Global Surgical sales grew 10.1% to $276.2 million, driven by the sustained market uptake of RESILIA therapies which offer extended durability.
  • Operating income expanded 28.1% year over year to $500.5 million, reflecting an operating margin expansion of 269 basis points to 30.4%.
  • Management raised its full-year 2026 sales growth guidance range from 8-10% to 9-11%, signaling confidence in continued market momentum.
  • The company strengthened its balance sheet with $2.40 billion in cash and cash equivalents while maintaining manageable debt levels around $600 million.
Risk Factors
  • Gross profit margins contracted by 64 basis points year over year to 78%, primarily due to a significant 20.2% increase in the cost of sales.
  • Cash and cash equivalents decreased from $3.00 billion in the fourth quarter of 2025 to $2.40 billion at the end of Q1 2026, indicating a drawdown in liquidity despite strong revenue growth.
  • The company's Q2 guidance for adjusted EPS is lower than Q1 results ($0.70-$0.76 vs the implied prior quarter strength), suggesting a potential peak in profitability this year.
Full Analysis
Edwards Lifesciences Corporation (EW) reported first-quarter 2026 adjusted earnings per share (EPS) of 78 cents, surpassing the Zacks Consensus Estimate by 16.4% and representing a 21.9% year-over-year increase. While sales totaled $1.65 billion, matching the consensus estimate, they grew 17% year over year. One-time adjustments primarily included litigation and restructuring expenses, with GAAP EPS from continuing operations at 66 cents compared to 62 cents in the prior period. Following the announcement, EW stock climbed 2.3% in aftermarket trading. The company attributed growth in its Transcatheter Aortic Valve Replacement (TAVR) group, which reached $1.20 billion globally, to heightened clinician focus on SAPIEN therapy and proactive disease management for severe aortic stenosis patients. Similarly, Transcatheter Mitral and Tricuspid Therapies (TMTT) sales rose 51.9% to $175.1 million due to the adoption of PASCAL and EVOQUE products. Financially, gross profit reached $1.29 billion, up 15.7%, though the gross margin contracted 64 basis points to 78% driven by a 20.2% increase in the cost of sales. SG&A expenses increased 12.1% to $522.2 million, while R&D expenditures rose modestly by 3.4% to $263.3 million. Despite these expenses, operating income jumped 28.1% year over year to $500.5 million, with the operating margin expanding significantly by 269 basis points to 30.4%. The company's cash and cash equivalents stood at $2.40 billion as of the end of the quarter, a decrease from $3.00 billion in the fourth quarter of 2025, while total debt remained roughly $600 million, consistent with the prior year. Looking ahead, Edwards raised its full-year 2026 outlook, projecting sales growth between 9% and 11%, which exceeds the Zacks Consensus Estimate pegged at 9.8%. Adjusted EPS for 2026 is now guided in the $2.95-$3.05 range, above the consensus of $2.96. For the second quarter of 2026, the company expects sales between $1.66 billion and $1.74 billion with adjusted EPS in the 70-76 cents range. Management highlighted continued growth drivers including the extended durability of RESILIA therapies in surgical operations, which includes INSPIRIS, KONECT, and MITRIS platforms. The article notes that while gross margin contraction is a concern, the expansion in operating margins remains a positive indicator, though EW currently holds a Zacks Rank #3 (Hold).